在非小细胞肺癌 (NSCLC) 中的MET:穿越"漫长而曲折的道路",寻找目标
Gianluca Spitaleri1, Pamela Trillo Aliaga1, Ilaria Attili1
1Division of Thoracic Oncology, IEO, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
非小细胞肺癌 (NSCLC) 的MET变化影响结果. 选择性MET抑制剂对MET外显子14跳转突变 (METex14) 和MET放大 (MET AMP) NSCLC有希望,提供新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 非小细胞肺癌 (NSCLC) 呈现出各种MET变异,包括过度表达 (MET OE),放大 (MET AMP) 和突变.
- 从历史上看,在MET-dysregulated NSCLC中确定特定的"可用药物"驱动因素是具有挑战性的,直到发现MET外显子14跳转突变 (METex14).
- 在约3%的NSCLC病例中发现了METex14的改变,并且在用免疫检查点抑制剂 (ICI) 治疗时与适度的疗效相关.
研究的目的:
- 审查NSCLC中MET变化的预后意义.
- 总结涉及选择性MET抑制剂 (MET-I) 的关键临床试验.
- 探索耐药性机制和MET向治疗NSCLC的未来方向.
主要方法:
- 对回顾性手术系列和临床试验的文献综述.
- 对NSCLC中MET变化的数据 (OE,AMP,突变,METex14) 的分析.
- 综合有关MET抑制剂有效性和耐药性的发现.
主要成果:
- 在NSCLC中MET失调与较差的临床结果有关.
- 选择性MET抑制剂在METex14 NSCLC中显示出显著的长期临床益处.
- MET抑制剂在MET AMP NSCLC中表现出适度的活性,目前正在对ADC等新型疗法进行研究.
结论:
- 在NSCLC中,MET变化起着至关重要的预后作用.
- 选择性MET抑制剂对于特定的MET改变NSCLC亚型来说是一个有前途的治疗策略.
- 需要进一步的研究来克服耐药性机制,并优化未来的MET向治疗.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
相关概念视频
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
